Volume 13, Issue 4 (Nov 2025)
Res Mol Med (RMM) 2025, 13(4): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sadeqi S, Yazdani Z, Zafari P, Ghafari S, Rafiei A. Cytotoxic Effects of Dimethylamino Parthenolide on the Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line. Res Mol Med (RMM) 2025; 13 (4)
URL: http://rmm.mazums.ac.ir/article-1-640-en.html
URL: http://rmm.mazums.ac.ir/article-1-640-en.html
1- Department of Immunology and Microbiology, Sari Medical School, Mazandaran University of Medical Sciences, Sari, Iran
2- Department of Immunology, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran.
3- Orthopedic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
4- Department of Immunology and Microbiology, Sari Medical School, Mazandaran University of Medical Sciences, Sari, Iran. ,rafiei1710@gmail.com
2- Department of Immunology, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran.
3- Orthopedic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
4- Department of Immunology and Microbiology, Sari Medical School, Mazandaran University of Medical Sciences, Sari, Iran. ,
Abstract: (32 Views)
Background: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which fibroblast-like synoviocytes (FLS) play a critical role in its pathogenesis. Due to the significant side effects associated with conventional treatments and the lack of response to the therapy in some patients, researchers are investigating novel therapeutic approaches that offer improved efficacy and a more favorable safety profile. This study aimed to investigate the cytotoxic activity of dimethylamino parthenolide (DMAPT) on the rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) cell line.
Methods: For this purpose, the RA-FLS cell line, previously generated in our unpublished studies, was treated with varying concentrations of DMAPT (0-160 μM) for 24 and 48 hours. Cell viability was assessed using the MTT assay. The half-maximal inhibitory concentration (IC₅₀) values were derived from dose-response curves fitted using GraphPad Prism software (version).
Results: Our results demonstrated that DMAPT exerts cytotoxic effects on the RA-FLS cell line, leading to a significant reduction in cell viability. This cytotoxic effect is dose-dependent, such that cell viability decreased with increasing dose. The half-maximal inhibitory concentration (IC ₅₀) values of DMAPT for rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) were 51.02 μM at 24 hours and 45.8 μM at 48 hours.
Conclusion: Our results demonstrated that DMAPT exerts cytotoxic effects on rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS).
Methods: For this purpose, the RA-FLS cell line, previously generated in our unpublished studies, was treated with varying concentrations of DMAPT (0-160 μM) for 24 and 48 hours. Cell viability was assessed using the MTT assay. The half-maximal inhibitory concentration (IC₅₀) values were derived from dose-response curves fitted using GraphPad Prism software (version).
Results: Our results demonstrated that DMAPT exerts cytotoxic effects on the RA-FLS cell line, leading to a significant reduction in cell viability. This cytotoxic effect is dose-dependent, such that cell viability decreased with increasing dose. The half-maximal inhibitory concentration (IC ₅₀) values of DMAPT for rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) were 51.02 μM at 24 hours and 45.8 μM at 48 hours.
Conclusion: Our results demonstrated that DMAPT exerts cytotoxic effects on rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS).
Keywords: Dimethylamino Parthenolide, DMAPT, Rheumatoid Arthritis, RAFLS, FLS, Fibroblast-Like Synoviocytes
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |